SPRY: ARS Pharma Kompaniya qiymatining sof foydaga nisbati

ARS Pharmaceuticals Inc (SPRY) korporativ emblemasi va logotipi

ARS Pharmaceuticals og'riqli inyeksiyalar o'rnini bosuvchi innovatsion efrafrin burun spreyi Neffy ni ishlab chiqmoqda. Kompaniyaning moslashtirilgan P/E ko'rsatkichi aktivning qiymat dinamikasini aks ettiradi, bunda -1.60 qiymati joriy darajani tavsiflaydi. Ignasiz yetkazib berish formati mahsulotni tengsiz yetakchi sifatida namoyish etib, bemorlar qulayligini oshiradi. Yechimning noyobligi a’lo darajadagi narx belgilash imkoniyatini va sug'urta tashkilotlari tomonidan premium stavkalarning tasdiqlanishini ta'minlaydi.

SPRY ARS Corp: Narx-foyda koeffitsiyenti 28.04.2023 - 10.11.2026 oraligʻida

ARS Pharma (SPRY) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi ars-pharma.com|SPRY - Konsensus maqsadli narx
- bozor kapitallashuvi haqida ma'lumot:
Bozor qiymati ARS Pharmaceuticals, Inc.|SPRY - Kompaniyaning to‘liq qiymati
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
Bitta aksiya hisobiga sof aktivlar qiymati ARS Pharmaceuticals|SPRY - Kompaniyaning sof aktivlari|Bozor kapitallashuvining balans qiymatiga multiplikatori ars-pharma.com|SPRY - Kompaniyaning umumiy aktivlari
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati ARS Pharmaceuticals|SPRY - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati ARS Corp|SPRY - Kompaniya qarzlari|Qarzning sof aktivlarga nisbati ARS Pharmaceuticals, Inc.|SPRY - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari ARS Pharmaceuticals|Oraliq qoplash koeffitsiyenti ars-pharma.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
SPRY - Kompaniyaning sof foydasi|Kompaniya foydasi prognozi ARS Pharmaceuticals|SPRY - Narx-foyda koeffitsiyenti|Kelajakdagi narx-foyda multiplikatori ARS Pharmaceuticals Inc|SPRY - Narxning foydaga va o‘sish sur’atiga nisbati|Kompaniya qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati ARS Pharmaceuticals, Inc.|SPRY - EBITDA operatsion foydasi|Sirpanuvchi yil uchun bir aksiya uchun foyda ARS Pharmaceuticals|SPRY - Bir aksiya uchun sof foyda (EPS TTM)|Choraklik EPS foyda o'sishi ars-pharma.com|SPRY - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning kutilayotgan dinamikasi ARS Pharmaceuticals
Kompaniyaning har tomonlama tahlili:ars-pharma.com - SPRY
ARS Pharmaceuticals, Inc. yetakchi tovari

Investorlar aktivning adolatli qiymatini bozor kapitalizatsiyasini biznesning sof daromad keltirishga bo'lgan haqiqiy qobiliyati bilan solishtirish orqali aniqlashlari kerak. Hisoblangan ushbu narx-foyda koeffitsienti investitsiyalarning qoplanish muddatini o'lchaydi, bu esa ARS Pharmaceuticals (SPRY) holatida innovatsion neffy dori vositasining joriy etilishi natijasida daromadning tez sur'atlarda o'sishi bilan ta'minlanib, tijorat kengayishi orqali kompaniyaning fundamental baholashini tubdan o'zgartirmoqda.

Muhim raqobatchilar

P/E multiplikatori haleon.com|Narx-foyda koeffitsiyenti KVUE (Kenvue)|VRNA (Verona Pharma PLC) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Jyong Biotech Corp MENS|Ligand Corp (LGND) - Kapitalizatsiyaning foydaga nisbati|AMRX: Narx-foyda koeffitsiyenti|perrigo.com - Bozor narxining sof foydaga nisbati|ALVO: P/E multiplikatori|Liquidia Corp - Kompaniya qiymatining sof foydaga nisbati|GLPG (Galapagos Genomics) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati ANI Pharmaceuticals Corp ANIP|Narxning foydaga nisbati MannKind Corporation (MNKD)|AMPH (amphastar.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori PCRX (Pacira BioSciences, Inc.)|P/E multiplikatori Theravance Biopharma Inc TBPH|AQST - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati SCPH (scPharmaceuticals Inc.)|tectonictx.com (TECX) - Narxning foydaga nisbati|TNXP - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti SXTC|EPRX: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati BioHarvest (BHST)|EXOZ: Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori ORMP (Oramed Pharmaceuticals Inc.)|Kompaniya qiymatining sof foydaga nisbati ENTX|MindWalk Holdings Inc. - P/E multiplikatori|ABVC - P/E multiplikatori|Cumberland Pharma (CPIX) - Narxning foydaga nisbati|Quantum BioPharma Corp - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati FibroGen, Inc.|Narx-foyda koeffitsiyenti telomirpharma.com (TELO)|P/E multiplikatori RANI|P/E multiplikatori synergychc.com (SNYR)|P/E multiplikatori RLYB (Rallybio)|LEXX - Narx-foyda koeffitsiyenti|Pulmatrix, Inc. - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Pheton Holdings Ltd|APM (aptorumgroup.com) - Narx-foyda koeffitsiyenti|Lyra Therapeutics Inc. (LYRA) - P/E multiplikatori|Narx-foyda koeffitsiyenti IBO|TNFA (TNF Pharma) - Bozor narxining sof foydaga nisbati|P/E multiplikatori YCBD|Biznesning o‘zini qoplash muddati painreform.com|P/E multiplikatori CYTO (Altamira Therapeutics Ltd.)|LIPO - Narx-foyda koeffitsiyenti|Optinose - P/E multiplikatori|PIRS - P/E multiplikatori|Procaps Group S.A. (PROC) - Narxning foydaga nisbati|PTPI (petrospharma.com) - Narxning foydaga nisbati|Narxning foydaga nisbati Qilian International Holding|Acelyrin Inc. (SLRN) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati TFF Pharma (TFFP)